CD13


Also found in: Acronyms.

CD13

a type II transmembrane protein found on myeloid cells that acts as a zinc-binding metalloprotease catalyzing removal of NH2-terminal amino acids from peptides; expressed in some types of acute nonlymphocytic leukemia.
References in periodicals archive ?
2010) CD13 is a therapeutic target in human liver cancer stem cells.
There was no significant correlation between NRP-1 RNA level and age, platelet count, LDH, BM blast %, CD33, CD13, CD14, CD61, myeloperoxidase, CD2, CD7, CD34, HLA-DR, CD10, or survival time.
Flow cytometry results showed a spectrum (94% of WBCs) of increased forward and side scatter, including CD33 on 100% of cells, CD13 on 64%, and a dim HLA-DR expression.
En la linea monocitica se encontraron diferencias estadisticamente significativas en la expresion de los marcadores CD45, CD13, CD11b, y CD14 en los monocitos respecto a promonocitos (Tabla 7; Figura 4).
Membrane markers revealed positivity for CD13, CD33, CD34, CD38, CD45, CD 117, and a HLA-DR 54.
Por otra parte, los neutrofilos tambien se benefician de esta interaccion, porque mantienen la expresion de CD13, CD15, CD16 y Mac-1, que son receptores de senales antiapoptoticas por medio de las cuales prolongaran su vida media.
Seven monoclonal antibodies for a set of leukocyte surface antigens (including CD13, CD15, CD33, CD34, HLA-DR, CD14, and CD45) have been immobilized on a modified slide (left side of Fig.
Flow cytometric analysis of a bone marrow biopsied sample showed involvement with > 30% blasts that were positive for CD13, CD33, CD34, CD117, CD19, and TdT-negative.
CD13 is expressed on approximately 25% of monocytes; CD33 is expressed by myeloblasts, promyelocytes, myelocytes, and mast cells, and throughout monocyte differentiation; and HLA-DR is positive in a myeloblastic population.
The monoclonal antibodies (MoAb) used for diagnosis of AL were: for B-lineage: CD19, CD22, CD20, CD10, for T-lineage: CD2, CD3, CD5, CD7, CD4, CD8, for myelo-monocytic lineage: CD13, CD33, CD11c, CD64, CD14, other cells surface markers: CD34, CD117, HLA-DR and intracellular MoAb: CD79a, CD3 and MPO.
The expression of CD13 is down-regulated in promyelocytes and returns to normal in myelocytes, metamyelocytes, and granulocytes.